Literature DB >> 21383088

Resistance to chloroquine unhinges vivax malaria therapeutics.

J Kevin Baird1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21383088      PMCID： PMC3088196          DOI： 10.1128/AAC.01296-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  23 in total

1.  Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine.

Authors:  A S ALVING; J ARNOLD; R S HOCKWALD; C B CLAYMAN; R J DERN; E BEUTLER; C L FLANAGAN
Journal:  J Lab Clin Med       Date:  1955-08

2.  THE CLINICAL TRIAL OF EIGHTEEN ANALOGUES OF PAMAQUIN (PLASMOCHIN) IN VIV AX MALARIA (CHESSON STRAIN).

Authors:  A S Alving; T N Pullman; B Craige; R Jones; C M Whorton; L Eichelberger
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

3.  PROCEDURES USED AT STATEVILLE PENITENTIARY FOR THE TESTING OF POTENTIAL ANTIMALARIAL AGENTS.

Authors:  A S Alving; B Craige; T N Pullman; C M Whorton; R Jones; L Eichelberger
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

4.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VII. THE ANTIMALARIAL ACTIVITY OF PAMAQUINE.

Authors:  R W Berliner; D P Earle; J V Taggart; W J Welch; C G Zubrod; P Knowlton; J A Atchley; J A Shannon
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

5.  Chemotherapy in Malaria.

Authors:  J A Shannon
Journal:  Bull N Y Acad Med       Date:  1946-07

6.  The Chesson strain of Plasmodium vivax malaria; relationship between prepatent period, latent period and relapse rate.

Authors:  B CRAIGE; A S ALVING
Journal:  J Infect Dis       Date:  1947 May-Jun       Impact factor: 5.226

7.  Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report.

Authors:  J H EDGCOMB; J ARNOLD; E H YOUNT; A S ALVING; L EICHELBERGER; G M JEFFERY; D EYLES; M D YOUNG
Journal:  J Natl Malar Soc       Date:  1950-12

Review 8.  The global distribution and population at risk of malaria: past, present, and future.

Authors:  Simon I Hay; Carlos A Guerra; Andrew J Tatem; Abdisalan M Noor; Robert W Snow
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

9.  Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India.

Authors:  Dhanpat K Kochar; Ashish Das; Sanjay K Kochar; Vishal Saxena; Parmendra Sirohi; Shilpi Garg; Abhishek Kochar; Mahesh P Khatri; Vikas Gupta
Journal:  Am J Trop Med Hyg       Date:  2009-02       Impact factor: 2.345

Review 10.  Shrinking the malaria map: progress and prospects.

Authors:  Richard G A Feachem; Allison A Phillips; Jimee Hwang; Chris Cotter; Benjamin Wielgosz; Brian M Greenwood; Oliver Sabot; Mario Henry Rodriguez; Rabindra R Abeyasinghe; Tedros Adhanom Ghebreyesus; Robert W Snow
Journal:  Lancet       Date:  2010-10-28       Impact factor: 79.321
View more
  37 in total

Review 1.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

Review 2.  Plasmodium vivax treatments: what are we looking for?

Authors:  Ric N Price; Nicholas M Douglas; Nicholas M Anstey; Lorenz von Seidlein
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

3.  Reinventing primaquine for endemic malaria.

Authors:  John Kevin Baird
Journal:  Expert Opin Emerg Drugs       Date:  2012-09-21       Impact factor: 4.191

Review 4.  Neurocysticercosis: a review on status in India, management, and current therapeutic interventions.

Authors:  Rumana Ahmad; Tahmeena Khan; Bilal Ahmad; Aparna Misra; Anil K Balapure
Journal:  Parasitol Res       Date:  2016-10-24       Impact factor: 2.289

5.  Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar.

Authors:  Lili Yuan; Ying Wang; Daniel M Parker; Bhavna Gupta; Zhaoqing Yang; Huaie Liu; Qi Fan; Yaming Cao; Yuping Xiao; Ming-chieh Lee; Guofa Zhou; Guiyun Yan; J Kevin Baird; Liwang Cui
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

6.  Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Authors:  Inge Sutanto; Bagus Tjahjono; Hasan Basri; W Robert Taylor; Fauziah A Putri; Rizka A Meilia; Rianto Setiabudy; Siti Nurleila; Lenny L Ekawati; Iqbal Elyazar; Jeremy Farrar; Herawati Sudoyo; J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

7.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641

8.  Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.

Authors:  Ann K Miller; Emma Harrell; Li Ye; Sharon Baptiste-Brown; Jőrg-Peter Kleim; Colin Ohrt; Stephan Duparc; Jörg J Möhrle; Alison Webster; Sandra Stinnett; Arlene Hughes; Sandy Griffith; Andrew P Beelen
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

9.  Single-nucleotide polymorphism and copy number variation of the multidrug resistance-1 locus of Plasmodium vivax: local and global patterns.

Authors:  Rosa del Carmen Miluska Vargas-Rodríguez; Melissa da Silva Bastos; Maria José Menezes; Pamela Orjuela-Sánchez; Marcelo U Ferreira
Journal:  Am J Trop Med Hyg       Date:  2012-09-04       Impact factor: 2.345

Review 10.  Primaquine treatment and relapse in Plasmodium vivax malaria.

Authors:  Kumar Rishikesh; Kavitha Saravu
Journal:  Pathog Glob Health       Date:  2016-02-18       Impact factor: 2.894
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.